| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
Purity: =99.04%
| Targets |
Cationic lipid for gene delivery
LP-01 is an ionizable cationic lipid that is used to formulate lipid nanoparticles (LNPs) for nucleic acid delivery. Its ionizable nature allows it to be positively charged at acidic pH, facilitating encapsulation of negatively charged nucleic acids, and neutral at physiological pH, reducing toxicity and improving circulation. The lipid targets the delivery of nucleic acids to cells and tissues. |
|---|---|
| ln Vitro |
CCD Lipid01 (LP-01 lipid) is useful in lipid nanopparticle formulation for delivery of genes (e.g. DNA and RNA vaccines).
In vitro, LP-01 is used to formulate LNPs for the delivery of mRNA, sgRNA, and other nucleic acids to cells. The LNPs facilitate cellular uptake and endosomal escape, enabling efficient gene expression or gene editing. The compound is used in cell-based assays to study gene function and to develop nucleic acid-based therapies. |
| ln Vivo |
In vivo, LP-01 is used to formulate LNPs for the delivery of nucleic acid-based vaccines and therapeutics. The LNPs are administered intravenously or intramuscularly to animal models. They facilitate the delivery of mRNA or DNA to target cells, leading to the production of therapeutic proteins or antigens. The compound has been used in the development of mRNA vaccines.
|
| Enzyme Assay |
In vitro, LNPs are formulated using LP-01, cholesterol, helper lipids, and PEG-lipids. The lipids are dissolved in ethanol and mixed with nucleic acids in an aqueous buffer to form LNPs by microfluidics or other methods. The resulting LNPs are characterized for size, polydispersity, and encapsulation efficiency. Cells are then treated with the LNPs, and nucleic acid delivery and expression are assessed.
|
| Animal Protocol |
In vivo, LNPs formulated with LP-01 are administered to animals via intravenous or intramuscular injection. The animals are monitored for the expression of the delivered nucleic acid, immune responses, and therapeutic efficacy. The LNPs facilitate the delivery of nucleic acids to target tissues, such as the liver or muscle. All procedures are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
LP-01 has a molecular weight of 852.27 and the chemical formula C₅₀H₉₃NO₉. It is an ionizable cationic lipid with a pKa of approximately 6.1. The lipid is soluble in organic solvents such as ethanol and DMSO. It should be stored at -20°C. The compound is for research use only and not for human therapeutic use.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for LP-01 are not extensively documented. As a lipid nanoparticle component, its toxicity is typically evaluated as part of the LNP formulation. The compound is for research use only and not for human therapeutic use. It should be handled with appropriate safety precautions, including the use of personal protective equipment. The compound should be stored in a sealed container in a cool, dry place away from incompatible materials.
|
| References | |
| Additional Infomation |
LP-01 is also known as CCD Lipid01 and CIN-16645. It is an ionizable cationic lipid used in the generation of LNPs for nucleic acid delivery. It has a pKa of approximately 6.1. It is used for the delivery of sgRNA, mRNA, and DNA vaccines. It is a lipid with a molecular weight of 852.27. It is supplied as a solid and should be stored at -20°C. It is for research use only.
|
| Molecular Formula |
C50H93NO9
|
|---|---|
| Molecular Weight |
852.2747
|
| Exact Mass |
851.685033
|
| Elemental Analysis |
C, 70.46; H, 11.00; N, 1.64; O, 16.89
|
| CAS # |
1799316-64-5
|
| Related CAS # |
CIN16645 HCl;1799316-64-5;
|
| PubChem CID |
118178658
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
15.5
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
49
|
| Heavy Atom Count |
60
|
| Complexity |
998
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])C([H])(C([H])([H])C([H])([H])C(=O)OC([H])([H])C([H])(C([H])([H])OC(=O)OC([H])([H])C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])[H])C([H])([H])OC(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C(/[H])=C(/[H])\C([H])([H])/C(/[H])=C(/[H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
| InChi Key |
CHTXXFZHKGGQGX-IFLFXUNCSA-N
|
| InChi Code |
InChI=1S/C50H93NO9/c1-6-11-14-17-20-21-22-23-24-25-26-27-28-29-32-36-47(52)58-43-46(45-60-50(54)57-42-35-39-51(9-4)10-5)44-59-48(53)37-38-49(55-40-33-30-18-15-12-7-2)56-41-34-31-19-16-13-8-3/h20-21,23-24,46,49H,6-19,22,25-45H2,1-5H3/b21-20-,24-23-
|
| Chemical Name |
[2-[3-(diethylamino)propoxycarbonyloxymethyl]-3-(4,4-dioctoxybutanoyloxy)propyl] (9Z,12Z)-octadeca-9,12-dienoate
|
| Synonyms |
1799316-64-5; CIN-16645; CCD Lipid01; CIN16645; (9Z,12Z)-3-((4,4-Bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9,12-dienoate; LP01; SCHEMBL16841239; EX-A7789;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~117.33 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (2.93 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1733 mL | 5.8667 mL | 11.7334 mL | |
| 5 mM | 0.2347 mL | 1.1733 mL | 2.3467 mL | |
| 10 mM | 0.1173 mL | 0.5867 mL | 1.1733 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA